Current Investigation

Learn About Your Legal Options Related to the Primus Recall of Limbrel

The FDA has announced that a recall of all unexpired Limbrel products is now underway by Primus Pharmaceuticals, Inc., which has marketed the osteoarthritis medication since 2004. This recall of Limbrel is the result of the FDA’s investigation into at least 30 complaints that the agency has received relating to “serious and reversible side effects associated with Limbrel.” The osteoarthritis medication has been marketed to physicians for over 13 years, with approximately 2 million prescriptions and physician samples of the medication provided to an estimated 450,000 patients. The products included in the recall include:

  • Limbrel (flavocoxid) 250 mg capsules
  • Limbrel250 (250 mg flavocoxid with 50 mg citrated zinc bisglycinate) capsules
  • Limbrel (flavocoxid) 500 mg capsules
  • Limbrel500 (500 mg flavocoxid with 50 mg citrated zinc bisglycinate) capsules

The FDA reports that the serious side effects experienced by patients include “elevated liver function tests or acute hypersensitivity pneumonitis.” The side effects can occur within a few weeks of use of Limbrel, but may not be noticed by the patient until a doctor consultation or until the symptoms worsen to the point that they require hospitalization. If you have taken Limbrel, and believe you may have experienced the serious side effects associated with the medication leading to the recall, you may be entitled to compensation. McCune Wright Arevalo, LLP, is a leading class action firm in California’s Inland Empire currently investigating the matter. Contact one of our attorneys today to learn about your legal options in pursuing financial recovery for your injuries related to Limbrel.

Call us for a free consultation about your legal matter at 909.557.1250 or fill out the form below.